Eur J Obstet Gynecol Reprod Biol. 2025 Sep 7;314:114707. doi: 10.1016/j.ejogrb.2025.114707. Online ahead of print.
ABSTRACT
OBJECTIVE: The first real-world experience of niraparib plus anlotinib after Poly(ADP-ribose) polymerase inhibitors (PARPi) resistance from China were investigated in patients with ovarian cancer.
METHODS: Patients treated with niraparib plus anlotinib after PARPi resistance in The Affiliated Cancer Hospital of Nanjing Medical University between December 2019 and February 2023 were enrolled. Eligible patients had histologically confirmed high-grade serous ovarian cancer. Objective response rate (ORR) and disease response rate (DCR) were evaluated by response evaluation criteria in solid tumours, version 1.1 (RECIST 1.1). Progression-free survival (PFS) and serum tumor marker fluctuations of Cancer Antigen 125 (CA125) and Human Epididymis Protein 4 (HE4) were also evaluated. Adverse events (AEs) were assessed by Common Terminology Criteria for Adverse Events (CTCAE 5.0).
RESULTS: Twenty-three patients treated with niraparib plus anlotinib had treated a median of two lines of chemotherapy. Most (73.9 %) of enrolled participants were BRCA-wildtype. The ORR and DCR of evaluable patients were 8.3 % and 83.3 %, respectively. The median PFS were 7.230 months for all patients. The median PFS of patients with different platinum status (8.465 months vs. 6.700 months, p = 0.343, initial dose of anlotinib (6.700 months vs. 7.930 months, p = 0.739) and prior use of bevacizumab or not (7.230 months vs. 7.030 months, p = 0.639) were similar. The most common grade 3-4 AEs were hand-foot syndrome and hypertension. No drug related death was reported.
CONCLUSIONS: Niraparib combined with anlotinib had promising antitumor activity and manageable AEs in the treatment of ovarian cancer after PARPi resistance.
PMID:40967072 | DOI:10.1016/j.ejogrb.2025.114707